Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Naurex Inc. logo — company profile

Naurex Inc.

Founded 2008 9 employees Series C Total: $162.11M Biopharma, Biotechnology +1

General Information

Company Name Naurex Inc.
Founded Year 2008
Founders / Decision Makers
Team member Team member
Employees 9
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Naurex Inc.. To contact Naurex Inc., visit naurex.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Naurex Inc. compare?

A PDF of Naurex Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Naurex Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Naurex Inc.

Naurex Inc., founded in 2008, is a biopharmaceutical company specializing in the development of innovative modulators of the NMDA receptor for the treatment of challenging brain and central nervous system disorders. The company's lead product candidate, rapastinel (GLYX-13), has displayed significant potential as an adjunctive therapy for patients with major depressive disorder who have not responded adequately to their current antidepressants. With promising results in Phase 2 clinical studies, rapastinel has shown rapid, substantial, and sustained antidepressant activity and has been well-tolerated, distinguishing itself from other NMDA receptor-targeting drugs by lacking psychosis-like side effects. Naurex's second-generation compound, NRX-1074, is also making strides and is currently in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder. The company attracted a notable $80.00M Series C investment on December 3, 2014, from a consortium of prominent investors including EcoR1 Capital, Genesys Capital Management Inc, Latterell Venture Partners, Takeda Pharma, Sabby Capital, Savitr Capital, Portal Capital, PathoCapital, Goudy Park Capital, and Druid BioVentures. This financial backing underscores the industry's confidence in Naurex's innovative approach to addressing mental health disorders. In a significant development, Naurex Inc. was acquired by Allergan plc in August 2015 following a definitive agreement in July 2015. For more information, interested parties can visit www.naurex.com or www.allergan.com. Naurex's focus on addressing unmet medical needs in mental health and the successful completion of its acquisition position it as a compelling player in the biopharmaceutical sector.

Business keywords: biopharmaceutical company, NMDA receptor modulators, major depressive disorder, rapastinel, NRX-1074, clinical development, antidepressant, psychosis-like side effects, Allergan plc, acquisition, central nervous system, neuroscience, drug development, pharmaceutical industry, clinical studies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $80.00M 10
EcoR1 Capital Genesys Capital Management Inc Latterell Venture Partners
EcoR1 Capital, Genesys Capital Management Inc +8
03 Dec 2014
Series C $25.00M 4
Takeda, Shire +2
06 May 2014
Series B $38.00M -
18 Dec 2012
Series A $18.00M 6
Adams Street Partners Genesys Capital Management Inc Latterell Venture Partners
Adams Street Partners, Genesys Capital Management Inc +4
11 May 2011
Debt Financing $1.11M -
04 Feb 2011

Naurex Inc. Alternatives & Competitors

View All Alternatives
Naurex Inc. vs
Cybin Inc
Cybin Inc Canada

We’re on a mission to revolutionize mental healthcare

Post-IPO Equity
73 employees
Biotechnology, Health Care
Naurex Inc. vs
Minerva Neurosciences
Minerva Neurosciences

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on...

Post-IPO Equity
9 employees
Biopharma, Biotechnology
Naurex Inc. vs
Reviva Pharmaceuticals
Reviva Pharmaceuticals United States

Next Generation Therapeutics to successfully address central nervous system, metabolic and respirato...

Post-IPO Equity
18 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Naurex Inc.

Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system. Our lead product candidate, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major de...
Naurex Inc. was founded in 2008.
Naurex Inc. operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on biopharmaceutical company, NMDA receptor modulators, major depressive disorder and rapastinel.
Naurex Inc. has approximately 9 employees.
Naurex Inc. has completed 5 funding rounds, raising a total of $162.11M. The latest funding stage is Series C.
Top alternatives and competitors to Naurex Inc. include Cybin Inc, Minerva Neurosciences, Reviva Pharmaceuticals, Afferent Pharmaceuticals, Cerebral Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Naurex Inc. and Cybin Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Naurex Inc., https://bouncewatch.com/company/naurex-inc, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout